Regioselectivity significantly impacts microsomal glucuronidation efficiency of R/S-6, 7-, and 8-hydroxywarfarin

References

• Barker W, Hermodson M, Link K. (1970). The metabolism of 4-C14-warfarin sodium by the rat. J Pharmacol Exp Ther 171:307–13.
   PubMed Web of Science ®Google Scholar
• Bock KW, Köhle C. (2009). Topological aspects of oligomeric UDP-glucuronosyltransferases in endoplasmic reticulum membranes: advances and open questions. Biochem Pharmacol 77:1458–65.
   PubMed Web of Science ®Google Scholar
• Bosma PJ, Seppen J, Goldhoorn B, et al. (1994). Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 269:17960–4.
   PubMed Web of Science ®Google Scholar
• Bratton SM, Mosher CM, Khallouki F, et al. (2012). Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases. J Pharmacol Exp Ther 340:46–55.
   PubMed Web of Science ®Google Scholar
• Breckenridge A, Orme M, Wesseling H, et al. (1974). Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 15:424–30.
   PubMed Web of Science ®Google Scholar
• Cavallari LH, Limdi NA. (2009). Warfarin pharmacogenomics. Curr Opin Mol Ther 11:243–51.
   PubMedGoogle Scholar
• Cheng Z, Rios GR, King CD, et al. (1998). Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. Toxicol Sci 45:52–7.
   PubMed Web of Science ®Google Scholar
• Ciotti M, Marrone A, Potter C, Owens IS. (1997). Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics 7:485
   PubMedGoogle Scholar
• Crespi C, Francis E, Patten C. 2009. Optimizing donor number for consistent pooled human liver microsomes. Billerica, MA: BD Biosciences–Discovery Labware.
   Google Scholar
• Danoff TM, Campbell DA, McCarthy LC, et al. (2003). A Gilbert’s syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. Pharmacogenomics J 4:49–53.
   Web of Science ®Google Scholar
• Doerge DR, Chang HC, Churchwell MI, Holder CL. (2000). Analysis of soy isoflavone conjugation in vitro and in human blood using liquid chromatography-mass spectrometry. Drug Metab Dispos 28:298–307.
   PubMed Web of Science ®Google Scholar
• Gaganis P, Miners JO, Knights KM. (2007). Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7. Biochem Pharmacol 73:1683–91.
   PubMed Web of Science ®Google Scholar
• Girard H, Court MH, Bernard O, et al. (2004). Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenet Genomics 14:501–15.
   Web of Science ®Google Scholar
• Harding D, Fournel-Gigleux S, Jackson MR, Burchell B. (1988). Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells. Proc Natl Acad Sci USA 85:8381–5.
   PubMed Web of Science ®Google Scholar
• Iyer L, King CD, Whitington PF, et al. (1998). Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847–54.
   PubMed Web of Science ®Google Scholar
• Jones DR, Boysen G, Miller GP. (2011). Novel multi-mode ultra performance liquid chromatography-tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasma. J Chromatogr B 879:1056–62.
   PubMed Web of Science ®Google Scholar
• Jones DR, Miller GP. (2011). Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know. Expert Opin Drug Metab Toxicol 7:857–74.
   PubMed Web of Science ®Google Scholar
• Jorgensen AL, Al-Zubiedi S, Zhang JE, et al. (2009). Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics 19:800–12.
   PubMed Web of Science ®Google Scholar
• Juurlink DN. (2007). Drug interactions with warfarin: what clinicians need to know. CMAJ 177:369–71.
   PubMed Web of Science ®Google Scholar
• Kaminsky LS, Zhang ZY. (1997). Human P450 metabolism of warfarin. Pharmacol Ther 73:67–74.
   PubMed Web of Science ®Google Scholar
• King CD, Rios GR, Assouline JA, Tephly TR. (1999). Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate. Arch Biochem Biophys 365:156–62.
   PubMed Web of Science ®Google Scholar
• Krishnaswamy S, Duan SX, von Moltke LL, et al. (2003). Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. Drug Metab Dispos 31:133–9.
   PubMed Web of Science ®Google Scholar
• Kuehl GE, Lampe JW, Potter JD, Bigler J. (2005). Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 33:1027–35.
   PubMed Web of Science ®Google Scholar
• Locatelli I, Kmetec V, Mrhar A, Grabnar I. (2005). Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. J Chromatogr B 818:191–8.
   PubMed Web of Science ®Google Scholar
• Miller G. (2010). Warfarin therapy: how the less interesting half just got interesting. J Thromb Haemost 8:2705–7.
   PubMed Web of Science ®Google Scholar
• Miller GP, Jones DR, Sullivan SZ, et al. (2009). Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol 22:1239–45.
   PubMed Web of Science ®Google Scholar
• Nagar S, Zalatoris JJ, Blanchard RL. (2004). Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenet Genomics 14:487–99.
   Web of Science ®Google Scholar
• Strassburg CP, Manns MP, Tukey RH. (1998). Expression of the UDP-glucuronosyltransferase 1A locus in human colon. J Biol Chem 273:8719–26.
   PubMed Web of Science ®Google Scholar
• Tachibana M, Tanaka M, Masubuchi Y, Horie T. (2005). Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyltransferase 1A subfamily in human liver microsomes. Drug Metab Dispos 33:803–11.
   PubMed Web of Science ®Google Scholar
• Udomuksorn W, Elliot DJ, Lewis BC, et al. (2007). Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics 17:1017–29.
   PubMed Web of Science ®Google Scholar
• Villeneuve L, Girard H, Fortier L-C, et al. (2003). Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-Ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 307:117–28.
   PubMed Web of Science ®Google Scholar
• Zielinska A, Lichti CF, Bratton S, et al. (2008). Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases. J Pharmacol Exp Ther 324:139–48.
   PubMed Web of Science ®Google Scholar